secwatch.observer — SEC 8-K summary
======================================

Issuer:     QUEST DIAGNOSTICS INC (DGX)
CIK:        0001022079
Form:       8-K
Filed at:   2026-10-22T10:49:59+00:00
Accession:  0001022079-26-000097
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Quest Diagnostics Q3 revenue $3.10B up 10%; adjusted EPS $3.00 up 15.4%; raises FY2026 guidance
--------------------------------------------------------------------------------

- Q3 net revenues $3.097B vs $2.816B; Diagnostic Information Services revenue $3.035B, up 10.2% YoY.
- Requisition volume rose 14.5% (organic +14.4%) while revenue per requisition fell 4.2%; reported diluted EPS $2.78, up 28.7%.
- Operating income $479M (15.5% of revenue); adjusted operating income $517M (16.7%); net income attributable to Quest $312M, up 27.6%.
- FY2026 guidance raised: revenue $12.065-$12.105B (prior $11.95-$12.05B), adjusted diluted EPS $11.25-$11.35 (prior $11.05-$11.25), operating cash flow ~$1.90B.
- Announced Quest lab panel with 50+ biomarkers sold via Apple Health app, definitive deal for Northeastern health system outreach lab assets, and AD-Detect pTau217 test launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/0001022079-26-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/dgx-20261022.htm
  HTML page:      https://secwatch.observer/filing/0001022079-26-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer